While the HR departments at Big Tech work overtime to craft exit packages and collect laptops from laid-off workers, companies also appear to be working overtime to repurchase stock.
While the HR departments at Big Tech work overtime to craft exit packages and collect laptops from laid-off workers, companies also appear to be working overtime to repurchase stock.
Alex Cristi /iStock via Getty Images Investment Thesis Figma ( FIG ) is one of the best digital product design platforms out there, but the changing nature of technology may impact its long-term viability. The main attraction behind Figma is that AI will expand usage of design tools and increase utilization of the platform. However, it will also streamline the way designers currently work and redu...
Alex Cristi /iStock via Getty Images Investment Thesis Figma ( FIG ) is one of the best digital product design platforms out there, but the changing nature of technology may impact its long-term viability. The main attraction behind Figma is that AI will expand usage of design tools and increase utilization of the platform. However, it will also streamline the way designers currently work and reduce the number of high-value customers that generate most of Figma's revenue. While Figma can grow its user base, its ability to charge higher prices per user will be diminished. As Figma moves towards a hybrid, AI-based consumption model, it will lose some of the predictability and durability in its SaaS business model. Additionally, by sacrificing short-term profitability to create this new model, the company is complicating the case around its fair valuation. In addition to these internal issues, external pressure has been building. Specifically, a large number of shares are coming off insider lock-up agreements, creating a significant amount of sellable stock. Competition has intensified as well from new AI-native design products that could potentially replace the need to use Figma altogether. While there is potential for Figma to evolve into the go-to interface for working within AI-assisted design environments, that end result hasn’t been demonstrated through the company's results. Therefore, given Figma's elevated non-GAAP P/E multiple of 82x, I'm rating the stock a Hold with a 12-month price target of $15.75. Figma's TAM Figma’s growth is tied to its TAM, which consists of the world’s design professionals and product teams. That market is decreasing, although not disappearing entirely. AI tools (Cursor, Lovable, v0, Claude Code) are reducing the number of individual design positions available at software companies. More senior engineers are creating interfaces using prompts, and product managers are using an AI tool to create prototypes without even considering Figma...
Kuehne & Nagel International ( KHNGF ): Q1 Revenue of $20B (flat Y/Y) beats by SEK12.46B . Adjusted EBITDA: Increased by 4.0% on a like-for-like basis to SEK 7.94 billion, driven by revenue growth and lower operational expenses. Operating Income: Decreased to SEK 3.1 billion (3.6 billion in Q1 2025). More on Kuehne + Nagel International AG Kuehne + Nagel International AG 2026 Q1 - Results - Earnin...
Kuehne & Nagel International ( KHNGF ): Q1 Revenue of $20B (flat Y/Y) beats by SEK12.46B . Adjusted EBITDA: Increased by 4.0% on a like-for-like basis to SEK 7.94 billion, driven by revenue growth and lower operational expenses. Operating Income: Decreased to SEK 3.1 billion (3.6 billion in Q1 2025). More on Kuehne + Nagel International AG Kuehne + Nagel International AG 2026 Q1 - Results - Earnings Call Presentation Kuehne+Nagel: Not An Attractive Play For Now Kuehne + Nagel International AG (KHNGY) Q4 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Kuehne + Nagel International AG Historical earnings data for Kuehne + Nagel International AG
FILE PHOTO: Psilocybin or "magic mushrooms" are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That comes after President Donald Trump signed an executiv...
FILE PHOTO: Psilocybin or "magic mushrooms" are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That comes after President Donald Trump signed an executive order on Saturday directing federal health agencies to expand access to emerging therapies. The move marks a significant shift toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, post-traumatic stress disorder and other substance use disorders, the FDA said. "Under President Trump's leadership, we are accelerating the research, approval and responsible access to promising mental health treatments," Robert F. Kennedy Jr., secretary of the U.S. Department of Health and Human Services, said in the release. "The FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement." As part of the announcement, the FDA said it would issue national priority vouchers to companies studying psilocybin for depression and methylone for PTSD. The agency also cleared an early-stage clinical trial for noribogaine hydrochloride, a derivative of ibogaine, as a potential treatment for alcohol use disorder. This is the first time a compound like it has been authorized for study in the U.S. "These medications have the potential to address the nation's mental health crisis," FDA Commissioner Marty Makary said in the announcement. "It is critical that their development is grounded in sound science and rigorous clinical evidence." The FDA said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective. Officials said data with be closely monitored as research advances. Choose CNBC as your preferred source on Google and never miss a moment from the most tru...